These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9180094)

  • 1. Preventing coronary restenosis and complications.
    Holmes DR
    N Engl J Med; 1997 Jun; 336(24):1748-9. PubMed ID: 9180094
    [No Abstract]   [Full Text] [Related]  

  • 2. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
    EPILOG Investigators
    N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Introduction: glycoprotein IIb/IIIa blockers in the era of metallic coronaries.
    Goldschmidt-Clermont PJ
    J Invasive Cardiol; 2002 Dec; 14 Suppl E():1E. PubMed ID: 12668856
    [No Abstract]   [Full Text] [Related]  

  • 4. Post-procedural patient management: prevention and management of bleeding complications.
    Aguirre F
    J Invasive Cardiol; 1994; 6 Suppl A():34A-37A; discussion 54A-56A. PubMed ID: 10155093
    [No Abstract]   [Full Text] [Related]  

  • 5. Prevention of restenosis after angioplasty.
    Cahill MR; Macey MG; Dawson JR; Newland AC
    Lancet; 1994 May; 343(8909):1361. PubMed ID: 7910347
    [No Abstract]   [Full Text] [Related]  

  • 6. A new therapeutic monoclonal antibody.
    Freeman PR
    J Am Pharm Assoc (Wash); 1996 Feb; NS36(2):90-1. PubMed ID: 8742006
    [No Abstract]   [Full Text] [Related]  

  • 7. Care of the patient receiving ReoPro following angioplasty.
    Brezina K; Murphy M; Stonner T
    J Invasive Cardiol; 1994; 6 Suppl A():38A-42A; discussion 54A-56A. PubMed ID: 10155094
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.
    EPIC Investigators
    N Engl J Med; 1994 Apr; 330(14):956-61. PubMed ID: 8121459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
    Popma JJ; Satler LF
    J Invasive Cardiol; 1994; 6 Suppl A():19A-28A; discussion 45A-50A. PubMed ID: 10155090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abciximab to prevent vessel closure after angioplasty.
    Med Lett Drugs Ther; 1995 Jun; 37(950):52-3. PubMed ID: 7760769
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roundtable panel discussion: the role of glycoprotein IIb-IIIa receptor inhibitors in acute ischemic coronary syndromes.
    White HD
    Am J Cardiol; 1997 Aug; 80(4A):44B-48B. PubMed ID: 9291246
    [No Abstract]   [Full Text] [Related]  

  • 13. Future trials of antiplatelet agents in cardiac ischemia.
    Throckmorton DC
    N Engl J Med; 2001 Jun; 344(25):1937-9. PubMed ID: 11419432
    [No Abstract]   [Full Text] [Related]  

  • 14. Minimally invasive bypass surgery.
    Dragu RE
    N Engl J Med; 2002 Dec; 347(26):2165-8; author reply 2165-8. PubMed ID: 12501850
    [No Abstract]   [Full Text] [Related]  

  • 15. Stents are the CADILLAC of care. Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications.
    SoRelle R
    Circulation; 2002 Apr; 105(14):e9094-5. PubMed ID: 11942340
    [No Abstract]   [Full Text] [Related]  

  • 16. [Medical progress exemplified by improvements in the safety coronary angioplasty].
    Metzger JP
    Bull Acad Natl Med; 2012 Oct; 196(7):1361-7; discussion 1367-8. PubMed ID: 23815020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelets and vascular thrombosis.
    Harker LA
    N Engl J Med; 1994 Apr; 330(14):1006-7. PubMed ID: 8121441
    [No Abstract]   [Full Text] [Related]  

  • 18. Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven?
    Lincoff AM; Topol EJ
    Eur Heart J; 2000 Jun; 21(11):863-7. PubMed ID: 10806004
    [No Abstract]   [Full Text] [Related]  

  • 19. Administering abciximab. A new drug for preventing coronary restenosis.
    Strimike CL; Wojcik JM
    Nursing; 1997 Mar; 27(3):32aa-32dd, 32ff. PubMed ID: 9171622
    [No Abstract]   [Full Text] [Related]  

  • 20. The platelet, the patient, and periprocedural infarction during percutaneous transluminal coronary angioplasty.
    Fischman DL; Savage MP
    JAMA; 1997 Aug; 278(6):518-9. PubMed ID: 9256229
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.